PharmaShots Weekly Snapshots (April 18-22, 2022)
Published: Apr 22, 2022 | Tags: Novavax, NVX-CoV2373, COVID-19, Vaccine Booster, P-III, PREVENT-19 Trial, COVID-19, Adolescents
Published: Apr 22, 2022 | Tags: Sanofi, Terran Biosciences, CNS Pipeline Assets, Neurological, Psychiatric Indications
Novavax Reports Results of COVID-19-Influenza Vaccine in P-I/II Trial for the Treatment of COVID-19
Published: Apr 22, 2022 | Tags: Novavax, COVID-19-Influenza Vaccine, P-I/II Trial, COVID-19
Orasis Reports Results of CSF-1 in P-III (NEAR-1 & 2) Trials for the Treatment of Presbyopia
Published: Apr 22, 2022 | Tags: Orasis, CSF-1, P-III, NEAR-1 & 2 Trials, Presbyopia
Published: Apr 22, 2022 | Tags: Zambon, CMS I-neb, US, FDA, Breakthrough Therapy Designation, Non-Cystic Fibrosis Bronchiectasis
Published: Apr 22, 2022 | Tags: Dragonfly, 2019, AbbVie, Therapies, Immune-Mediated Diseases
Published: Apr 21, 2022 | Tags: Servier, Tibsovo, ivosidenib, P-III, AGILE Trial, IDH1-Mutated, Acute Myeloid Leukemia, NEJM
Published: Apr 21, 2022 | Tags: Ultragenyx, Setrusumab, UX143, P-II/III, Orbit Study Osteogenesis Imperfecta
Otonomy Reports Results of OTO-413 in P-IIa Clinical Trial for the Treatment of Hearing Loss
Published: Apr 21, 2022 | Tags: Otonomy, OTO-413, P-IIa, Clinical Trial, Hearing Loss
Published: Apr 21, 2022 | Tags: AstraZeneca, Evusheld, P-III, PROVENT Trial, Symptomatic COVID-19
Published: Apr 21, 2022 | Tags: Vertex, Health Canada, Marketing Authorization, Trikafta, elexacaftor, tezacaftor,ivacaftor, Cystic Fibrosis
Published: Apr 21, 2022 | Tags: VantAI, Boehringer Ingelheim, Novel Protein Degraders, Geometric Deep Learning Platform
Published: Apr 20, 2022 | Tags: AlloVir, Posoleucel, US, FDA, RMAT, Designation, Allogeneic Hematopoietic Cell Transplant
Published: Apr 20, 2022 | Tags: Idorsia, Pivlaz, clazosentan, MHLW, Approval, Aneurysmal Subarachnoid Hemorrhage, Japan
Published: Apr 20, 2022 | Tags: Bavarian Nordic, P-III, VANIR Trial, Respiratory Syncytial Virus
Published: Apr 20, 2022 | Tags: INmune Bio, P-II, XPro1595 Trial, Neuroinflammation, Alzheimer Disease
Published: Apr 20, 2022 | Tags: SpringWorks, Regeneron, Nirogacestat, REGN5458, Multiple Myeloma
Published: Apr 20, 2022 | Tags: Ono, Domain, Université de Montréal, Small Molecules, G-Protein Coupled Receptors
Published: Apr 19, 2022 | Tags: Neuraly, P-II Study, NLY01, Parkinson’s Disease
Published: Apr 19, 2022 | Tags: BeiGene, Tislelizumab, P-III, RATIONALE-309 Trial, Nasopharyngeal Cancer, ASCO, 2022
Published: Apr 19, 2022 | Tags: Daiichi Sankyo, AstraZeneca, US, FDA, Enhertu, Priority Review, HER2 Mutant, Metastatic, Non-Small Cell Lung Cancer
Takeda’s Nuvaxovid COVID-19 Vaccine Receives the MHLW Approval for the Treatment of COVID-19
Published: Apr 19, 2022 | Tags: Takeda, Nuvaxovid, COVID-19 Vaccine, MHLW, Approval, COVID-19
Published: Apr 19, 2022 | Tags: Amgen, ABP 654, biosimilar, ustekinumab, P-III Study, Plaque Psoriasis
Published: Apr 19, 2022 | Tags: Biocytogen, CtM Biotech, TCR-Mimic, Antibody-Based, Multi-Specific, T Cell, Engagers, Cancer
Published: Apr 18, 2022 | Tags: Black Diamond, First Patient Dosing, P-I Study, BDTX-1535, Glioblastoma, Non-Small Cell Lung Cancer
Evelo Reports the Clinical Hold on EDP1867 Program for the Treatment of Atopic Dermatitis
Published: Apr 18, 2022 | Tags: Evelo, Clinical Hold, EDP1867, Program, Atopic Dermatitis
Published: Apr 18, 2022 | Tags: US, FDA, BLA, Regeneron, REGEN-COV, COVID-19
The US FDA Approved First Breathalyzer to Detect COVID-19
Published: Apr 18, 2022 | Tags: US, FDA, Approved, Breathalyzer, Detect, COVID-19, EUA, InspectIR
TG Therapeutics Voluntary Withdrawal BLA/sNDA of U2 for Patients with CLL and SLL
Published: Apr 18, 2022 | Tags: TG Therapeutics, Voluntary Withdrawal, BLA, sNDA, U2, CLL, SLL, ublituximab, Ukoniq
Published: Apr 18, 2022 | Tags: BeiGene, Tislelizumab, NMPA, Approval, 2L, Esophageal Squamous Cell Carcinoma
Related Post: PharmaShots Weekly Snapshots (April 11-15, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com